Natera, Inc. $NTRA Position Increased by PointState Capital LP

Key Points

• PointState Capital LP increased its stake in Natera, Inc. by 32.8% in Q1, now owning approximately $106.87 million worth of shares, making it the 17th largest position in their portfolio.
• Natera reported a loss of $0.74 EPS for the last quarter, missing estimates, but achieved revenues of $546.6 million, surpassing analyst expectations.
• Insider transactions included the CEO and another executive selling over 6,400 shares, indicating a decrease in their ownership but still retaining substantial shares valued at over $45 million.

PointState Capital LP raised its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 32.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 755,729 shares of the medical research company's stock after acquiring an additional 186,477 shares during the quarter. Natera makes up 1.5% of PointState Capital LP's investment portfolio, making the stock its 17th largest position. PointState Capital LP owned approximately 0.56% of Natera worth $106,868,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. HighPoint Advisor Group LLC boosted its stake in shares of Natera by 30.8% during the 1st quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company's stock worth $308,000 after purchasing an additional 468 shares during the last quarter. Amalgamated Bank boosted its stake in shares of Natera by 9.8% during the 1st quarter. Amalgamated Bank now owns 8,293 shares of the medical research company's stock worth $1,173,000 after purchasing an additional 740 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Natera by 32.3% during the 1st quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock worth $120,000 after purchasing an additional 207 shares during the last quarter. Comerica Bank boosted its stake in shares of Natera by 24.1% during the 1st quarter. Comerica Bank now owns 141,106 shares of the medical research company's stock worth $19,954,000 after purchasing an additional 27,379 shares during the last quarter. Finally, Teza Capital Management LLC acquired a new stake in shares of Natera during the 4th quarter worth about $221,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Stock Up 1.8%

Shares of NTRA traded up $3.12 during mid-day trading on Thursday, reaching $172.91. 258,441 shares of the stock traded hands, compared to its average volume of 1,470,432. The firm has a market cap of $23.73 billion, a price-to-earnings ratio of -90.47 and a beta of 1.68. The stock has a fifty day simple moving average of $154.79 and a 200 day simple moving average of $153.98. Natera, Inc. has a 12-month low of $117.27 and a 12-month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The firm had revenue of $546.60 million for the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company's revenue for the quarter was up 32.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

NTRA has been the topic of several analyst reports. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 price target on the stock in a research note on Monday, July 28th. Morgan Stanley reaffirmed an "overweight" rating and set a $195.00 price target on shares of Natera in a research note on Sunday, August 10th. Piper Sandler reissued an "overweight" rating and issued a $220.00 target price (up from $210.00) on shares of Natera in a research report on Monday, August 11th. Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Finally, Cowen reissued a "buy" rating on shares of Natera in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company's stock. According to data from MarketBeat.com, Natera has an average rating of "Buy" and a consensus price target of $194.00.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 5,079 shares of Natera stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $166.53, for a total value of $845,805.87. Following the completion of the sale, the chief executive officer owned 158,514 shares in the company, valued at approximately $26,397,336.42. The trade was a 3.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Rowan E. Chapman sold 2,750 shares of Natera stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total transaction of $459,222.50. Following the completion of the sale, the director owned 6,015 shares of the company's stock, valued at approximately $1,004,444.85. This trade represents a 31.37% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 56,423 shares of company stock valued at $8,459,656. 5.63% of the stock is owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.